Drugs that target MUC5AC (ENSITUXIMAB) and STAT6 (CHEMBL363332 and CHEMBL1374370) have emerged as potential avenues of future research via repurposing for severe asthma and show these two proteins are viable therapeutic targets. The gene discussed is STAT6; the disease is asthma.